Jessica S Jarmasz1, Alexandrea Anderson2, Margaret E Bock1, Yan Jin1, Peter A Cattini1, Chelsea Ruth3. 1. Department of Physiology and Pathophysiology, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, 419-745 Bannatyne Avenue, Winnipeg, MB, R3E 0J9, Canada. 2. Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, 408-727 McDermot Avenue, Winnipeg, MB, R3E 2P5, Canada. 3. Department of Pediatrics and Child Health, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, 408-727 McDermot Avenue, Winnipeg, MB, R3E 2P5, Canada. Chelsea_Ruth@umanitoba.ca.
Abstract
BACKGROUND: Studies have found an association between obesity and an increased risk for peripartum depression, which has also been linked to decreased placental lactogen levels. In addition, women with obesity treated for gestational diabetes with insulin were found to have increased levels of placental lactogen. Treatment options exist for perinatal and postpartum depression however they pose a risk to the developing offspring. Thus, prevention as well as markers for early identification of peripartum depression are needed. Therefore, our study objective is to identify the association between insulin treatment in pregnancy and the risk of postpartum psychological distress (abbreviated here as PPD) among cohorts of women with and without obesity. METHODS: Administrative health data (2002/03-2018/19) were used to identify a cohort of women (age 15+ years) who gave birth (N = 250,746) and had no pre-existing mood/anxiety disorders or diabetes (N = 222,863 excluded). Women were then divided into two groups: lean (N = 17,975) and with obesity (N = 9908), which was identified by a recorded maternal weight of > 38 to < 65.6 kg and ≥ 85 to < 186 kg (respectively). The risk of PPD within one year after delivery with and without insulin treatment was assessed by Poisson regression analysis. Models were adjusted for maternal age group (at pregnancy start date) and area-level income (at delivery). RESULTS: The unadjusted risk of PPD was higher in the obesity group (8.56%; 95% CI 8.00-9.15) than in the lean group (6.93%; 95% CI 6.56-7.33). When no insulin treatment was given during pregnancy, mothers with obesity had a significantly higher risk of PPD than the lean group (aRR 1.27; 95% CI 1.17-1.39; p < 0.0001). However, when women with obesity and insulin treatment were compared to the lean group with no insulin treatment, no significant difference in the risk of PPD was observed between the groups (aRR 1.30; 95% CI 0.83-2.02; p = 0.248). CONCLUSION: This is the first study to demonstrate a positive association between insulin treatment in pregnancy among women with obesity and reduced PPD rates, suggesting insulin as a possible preventative measure. However, the biological mechanism behind the observed positive effect of insulin on PPD rates remains to be investigated.
BACKGROUND: Studies have found an association between obesity and an increased risk for peripartum depression, which has also been linked to decreased placental lactogen levels. In addition, women with obesity treated for gestational diabetes with insulin were found to have increased levels of placental lactogen. Treatment options exist for perinatal and postpartum depression however they pose a risk to the developing offspring. Thus, prevention as well as markers for early identification of peripartum depression are needed. Therefore, our study objective is to identify the association between insulin treatment in pregnancy and the risk of postpartum psychological distress (abbreviated here as PPD) among cohorts of women with and without obesity. METHODS: Administrative health data (2002/03-2018/19) were used to identify a cohort of women (age 15+ years) who gave birth (N = 250,746) and had no pre-existing mood/anxiety disorders or diabetes (N = 222,863 excluded). Women were then divided into two groups: lean (N = 17,975) and with obesity (N = 9908), which was identified by a recorded maternal weight of > 38 to < 65.6 kg and ≥ 85 to < 186 kg (respectively). The risk of PPD within one year after delivery with and without insulin treatment was assessed by Poisson regression analysis. Models were adjusted for maternal age group (at pregnancy start date) and area-level income (at delivery). RESULTS: The unadjusted risk of PPD was higher in the obesity group (8.56%; 95% CI 8.00-9.15) than in the lean group (6.93%; 95% CI 6.56-7.33). When no insulin treatment was given during pregnancy, mothers with obesity had a significantly higher risk of PPD than the lean group (aRR 1.27; 95% CI 1.17-1.39; p < 0.0001). However, when women with obesity and insulin treatment were compared to the lean group with no insulin treatment, no significant difference in the risk of PPD was observed between the groups (aRR 1.30; 95% CI 0.83-2.02; p = 0.248). CONCLUSION: This is the first study to demonstrate a positive association between insulin treatment in pregnancy among women with obesity and reduced PPD rates, suggesting insulin as a possible preventative measure. However, the biological mechanism behind the observed positive effect of insulin on PPD rates remains to be investigated.
Entities:
Keywords:
Administrative data; Epidemiology; Gestational diabetes; Human placental lactogen; Insulin; Maternal obesity; Mood and anxiety disorder; Postpartum psychological distress; Pregnancy
Authors: Teresa Kulie; Andrew Slattengren; Jackie Redmer; Helen Counts; Anne Eglash; Sarina Schrager Journal: J Am Board Fam Med Date: 2011 Jan-Feb Impact factor: 2.657
Authors: Shayna D Cunningham; Shilpa Mokshagundam; Hannah Chai; Jessica B Lewis; Jessica Levine; Jonathan N Tobin; Jeannette R Ickovics Journal: J Midwifery Womens Health Date: 2018-03-23 Impact factor: 2.388
Authors: Yan Jin; Hana Vakili; Song Yan Liu; Savas Menticoglou; Margaret E Bock; Peter A Cattini Journal: Am J Physiol Endocrinol Metab Date: 2018-05-15 Impact factor: 4.310
Authors: Elisabeth B Binder; D Jeffrey Newport; Elizabeth B Zach; Alicia K Smith; Todd C Deveau; Lori L Altshuler; Lee S Cohen; Zachary N Stowe; Joseph F Cubells Journal: J Psychiatr Res Date: 2009-12-31 Impact factor: 4.791
Authors: Solja T Nyberg; G David Batty; Jaana Pentti; Marianna Virtanen; Lars Alfredsson; Eleonor I Fransson; Marcel Goldberg; Katriina Heikkilä; Markus Jokela; Anders Knutsson; Markku Koskenvuo; Tea Lallukka; Constanze Leineweber; Joni V Lindbohm; Ida E H Madsen; Linda L Magnusson Hanson; Maria Nordin; Tuula Oksanen; Olli Pietiläinen; Ossi Rahkonen; Reiner Rugulies; Martin J Shipley; Sari Stenholm; Sakari Suominen; Töres Theorell; Jussi Vahtera; Peter J M Westerholm; Hugo Westerlund; Marie Zins; Mark Hamer; Archana Singh-Manoux; Joshua A Bell; Jane E Ferrie; Mika Kivimäki Journal: Lancet Public Health Date: 2018-09-01
Authors: A B Janssen; L E Capron; K O'Donnell; S J Tunster; P G Ramchandani; A E P Heazell; V Glover; R M John Journal: Psychol Med Date: 2016-08-15 Impact factor: 7.723